01—Abstract
Summary
Summary of the 8-K filed October 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Insmed Incorporated (Nasdaq: INSM) reported third-quarter 2025 financial results on October 30, 2025, highlighting the first full-quarter contribution from BRINSUPRI (brensocatib), approved by the FDA in August 2025 for non-cystic fibrosis bronchiectasis.
Total revenues were $142.3 milliona for the quarter, versus $93.4 million a year earlier, comprising $114.3 million of ARIKAYCE revenue (up 22% year over year) and $28.1 million of BRINSUPRI U.S. revenue. The company reported a net loss of $370.0 million, or $1.75 per share, compared with a net loss of $220.5 million, or $1.27 per share, in the prior-year quarter. Operating expenses rose sharply, with R&D at $186.4 million and SG&A at $186.4 million, both driven by BRINSUPRI commercial readiness and clinical development.
The company raised its full-year 2025 global ARIKAYCE revenue guidance to $420 million to $430 millionb, up from $405 million to $425 million. Cash, cash equivalents and marketable securities totaled approximately $1.7 billion as of September 30, 2025. Management stated that the BRINSUPRI results are promising but do not yet represent final contracting and access dynamics, and that inventory stocking accounted for roughly 40% of third-quarter sales.
Near-term catalysts include topline data from the Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps by early January 2026, topline data from the Phase 2b CEDAR study in hidradenitis suppurativa in the first half of 2026, and the Phase 3 ENCORE readout for ARIKAYCE in the first half of 2026. The company also expects a Phase 3 PALM-ILD study of TPIP to begin in the fourth quarter of 2025.
02—Key points
Key Highlights
- Total Q3 2025 revenues of $142.3 million, up from $93.4 million in Q3 2024, with BRINSUPRI contributing $28.1 million in its first partial quarter
- ARIKAYCE Q3 revenue of $114.3 million, up 22% year over year, with U.S. revenue of $74.0 million and international revenue of $40.3 million
- Net loss widened to $370.0 million ($1.75 per share) from $220.5 million ($1.27 per share) a year earlier
- Full-year 2025 global ARIKAYCE revenue guidance raised to $420 million to $430 million from $405 million to $425 million
- Cash, cash equivalents and marketable securities of approximately $1.7 billion as of September 30, 2025
- Management noted inventory stocking accounted for about 40% of Q3 BRINSUPRI-related sales and said it does not expect a similar contribution in Q4
- BRINSUPRI received a positive CHMP opinion in the EU, with UK and Japan regulatory submissions accepted
03—Questions
Frequently Asked Questions
How did BRINSUPRI perform in its first quarter on the market?
BRINSUPRI generated $28.1 million in U.S. net sales for the period ended September 30, 2025, its first partial quarter after the August 2025 FDA approval. Management stated that the results are promising but do not yet reflect final contracting and access dynamics, and that about 40% of Q3 sales came from inventory stocking.
Why did operating expenses increase so significantly?
Total operating expenses were $508.3 million in Q3 2025 versus $306.9 million in Q3 2024. The filing attributes the increases in R&D and SG&A to headcount growth, stock-based compensation, clinical development costs, and professional fees tied to BRINSUPRI commercial readiness and activities. The change in fair value of deferred and contingent consideration liabilities was $104.7 million in the quarter.
What are the key upcoming catalysts for investors?
The company expects topline data from the Phase 2b BiRCh study in CRSsNP by early January 2026, topline data from the Phase 2b CEDAR study in hidradenitis suppurativa in the first half of 2026, and topline data from the Phase 3 ENCORE trial of ARIKAYCE in the first half of 2026. A Phase 3 PALM-ILD study of TPIP is expected to begin in the fourth quarter of 2025.
How much revenue did ARIKAYCE generate and what is the updated outlook?
ARIKAYCE generated $114.3 million in Q3 2025 revenue, up 22% from the prior-year quarter, and $314.5 million for the nine months ended September 30, 2025. The company raised its full-year 2025 global ARIKAYCE revenue guidance to $420 million to $430 million, representing 15% to 18% year-over-year growth compared with 2024.
04—Continue